Serial No. 199904. 168 TRADEMARY Inventor(s) Ashkenazi et al.



02-04-02

0300 DEC To 9700

Case No. 10466/70 TRANSMITTAL LETTER Filing Date July 12, 2001 Examiner Group Art Unit 1645 To be assigned Title of Invention
SE_IRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

Ţ	TO THE COMMISSIONER FOR PATENTS										
Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); paper copy of Sequence Listing; copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard.											
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.										
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.										
	Petition for amonth extension of time.										
\boxtimes	No additional fee is required.										
	The fee has been calculated as shown below:										
d	Other Than Small Entity Small Entity										
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'l Fee	or	Rate	Add'I Fee	
Total	,	Minus				x \$9=		-	x \$18=		
Indep.		Minus	<u>.</u>			x 42=		1	x \$84=		
First Presentation of Multiple Dep. Claim +\$140=									+ \$280=		
						Total add'l fee	\$]	Total add'l fee	\$	
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.										
	A check in the amount of \$ to cover the filing fee is enclosed.										
	The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.										
	I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.										
	Respectfully submitted,										
Im Bull											
Gregory M. Zinkl, Ph.D. Registration No. 48,492											
Agent for Applicant BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200											
I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, tabel no. EL 392680676US, with sufficient postage fin an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on											
Date: 02/01/02 Signature: ###											
rev. Dec00											



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

www.uspto.gov FILING/RECEIPT DATE APPLICATION NUMBE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER 09/904,766 07/12/2001 Avi Ashkenazi P1618P2C33 FEB 0 1 2002 **CONFIRMATION NO. 4054 FORMALITIES LETTER** Brinks Hofer Gilson & Lione Paul E. Rauch, Ph. 100 Brinks, Hofer, Gilson OC000000007164304* NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599 Date Mailed: 12/06/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY